Compugen Ltd (CGEN) — 分析摘要
Compugen Ltd（CGEN）的市值为261.45百万美元，最近一年的营收同比增长了+161.1%。净利润率为48.6%。当前市盈率为7.4倍。
核心要点
- 营收同比变化+161.1%
- 净利润率48.6%
- 市盈率7.4倍
CGEN的营收增长为+161.1%，市盈率为7.4倍。
Compugen Ltd (CGEN)
更新 — ET · 市场数据 POLYGON · 财务数据 SEC EDGAR
红旗与风险提示无重大红旗
基于最新财报，没有触发重大的信用、利润率或趋势红旗。
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.
员工人数
75
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。